Hepatic manifestations of women with polycystic ovary syndrome

Mei Jou Chen, Hong Nerng Ho

Research output: Contribution to journalReview article

10 Citations (Scopus)

Abstract

Women with polycystic ovary syndrome (PCOS) have a higher prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) than the general population. The link between NAFLD/NASH and PCOS is not just a coincidence. Indeed, both of these disorders comprise common risk factors, including central obesity, insulin resistance, chronic low-grade inflammation, and hyperandrogenemia. The characteristics of hyperandrogenemia in women with PCOS include elevated total and free testosterone levels and low sex hormone-binding globulin levels and are reported to be associated with NAFLD and elevated liver enzymes; however, not all elevated androgen levels in women with PCOS have the same adverse effects on the liver. With the exception of weight loss and encouraging exercise in obese women, few evidence-based effective treatments target NAFLD/NASH in women with PCOS. Selective antiandrogens and insulin sensitizers might be beneficial in treating NAFLD/NASH in women with PCOS, but further elucidation is needed.

Original languageEnglish
Pages (from-to)119-128
Number of pages10
JournalBest Practice and Research: Clinical Obstetrics and Gynaecology
Volume37
DOIs
Publication statusPublished - Nov 1 2016
Externally publishedYes

Fingerprint

Polycystic Ovary Syndrome
Liver
Non-alcoholic Fatty Liver Disease
Androgen Antagonists
Sex Hormone-Binding Globulin
Abdominal Obesity
Androgens
Insulin Resistance
Testosterone
Weight Loss
Exercise
Insulin
Inflammation
Enzymes

Keywords

  • androgen
  • hepatic steatosis
  • liver enzyme
  • nonalcoholic fatty liver disease
  • polycystic ovary syndrome

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Hepatic manifestations of women with polycystic ovary syndrome. / Chen, Mei Jou; Ho, Hong Nerng.

In: Best Practice and Research: Clinical Obstetrics and Gynaecology, Vol. 37, 01.11.2016, p. 119-128.

Research output: Contribution to journalReview article

@article{72215c381b594731a4a8893172347438,
title = "Hepatic manifestations of women with polycystic ovary syndrome",
abstract = "Women with polycystic ovary syndrome (PCOS) have a higher prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) than the general population. The link between NAFLD/NASH and PCOS is not just a coincidence. Indeed, both of these disorders comprise common risk factors, including central obesity, insulin resistance, chronic low-grade inflammation, and hyperandrogenemia. The characteristics of hyperandrogenemia in women with PCOS include elevated total and free testosterone levels and low sex hormone-binding globulin levels and are reported to be associated with NAFLD and elevated liver enzymes; however, not all elevated androgen levels in women with PCOS have the same adverse effects on the liver. With the exception of weight loss and encouraging exercise in obese women, few evidence-based effective treatments target NAFLD/NASH in women with PCOS. Selective antiandrogens and insulin sensitizers might be beneficial in treating NAFLD/NASH in women with PCOS, but further elucidation is needed.",
keywords = "androgen, hepatic steatosis, liver enzyme, nonalcoholic fatty liver disease, polycystic ovary syndrome",
author = "Chen, {Mei Jou} and Ho, {Hong Nerng}",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.bpobgyn.2016.03.003",
language = "English",
volume = "37",
pages = "119--128",
journal = "Best Practice and Research in Clinical Obstetrics and Gynaecology",
issn = "1521-6934",
publisher = "Bailliere Tindall Ltd",

}

TY - JOUR

T1 - Hepatic manifestations of women with polycystic ovary syndrome

AU - Chen, Mei Jou

AU - Ho, Hong Nerng

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Women with polycystic ovary syndrome (PCOS) have a higher prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) than the general population. The link between NAFLD/NASH and PCOS is not just a coincidence. Indeed, both of these disorders comprise common risk factors, including central obesity, insulin resistance, chronic low-grade inflammation, and hyperandrogenemia. The characteristics of hyperandrogenemia in women with PCOS include elevated total and free testosterone levels and low sex hormone-binding globulin levels and are reported to be associated with NAFLD and elevated liver enzymes; however, not all elevated androgen levels in women with PCOS have the same adverse effects on the liver. With the exception of weight loss and encouraging exercise in obese women, few evidence-based effective treatments target NAFLD/NASH in women with PCOS. Selective antiandrogens and insulin sensitizers might be beneficial in treating NAFLD/NASH in women with PCOS, but further elucidation is needed.

AB - Women with polycystic ovary syndrome (PCOS) have a higher prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) than the general population. The link between NAFLD/NASH and PCOS is not just a coincidence. Indeed, both of these disorders comprise common risk factors, including central obesity, insulin resistance, chronic low-grade inflammation, and hyperandrogenemia. The characteristics of hyperandrogenemia in women with PCOS include elevated total and free testosterone levels and low sex hormone-binding globulin levels and are reported to be associated with NAFLD and elevated liver enzymes; however, not all elevated androgen levels in women with PCOS have the same adverse effects on the liver. With the exception of weight loss and encouraging exercise in obese women, few evidence-based effective treatments target NAFLD/NASH in women with PCOS. Selective antiandrogens and insulin sensitizers might be beneficial in treating NAFLD/NASH in women with PCOS, but further elucidation is needed.

KW - androgen

KW - hepatic steatosis

KW - liver enzyme

KW - nonalcoholic fatty liver disease

KW - polycystic ovary syndrome

UR - http://www.scopus.com/inward/record.url?scp=84963936616&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84963936616&partnerID=8YFLogxK

U2 - 10.1016/j.bpobgyn.2016.03.003

DO - 10.1016/j.bpobgyn.2016.03.003

M3 - Review article

C2 - 27107966

AN - SCOPUS:84963936616

VL - 37

SP - 119

EP - 128

JO - Best Practice and Research in Clinical Obstetrics and Gynaecology

JF - Best Practice and Research in Clinical Obstetrics and Gynaecology

SN - 1521-6934

ER -